Jeffrey J VanWormer1, Christie M Bartels2, Sara S McCoy3, Scott Hetzel4,5. 1. Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA. 2. Department of Medicine, School of Medicine and Public Health, University of Wisconsin, 1685 Highland Avenue, Madison, WI, 53705-2281, USA. 3. Department of Medicine, School of Medicine and Public Health, University of Wisconsin, 1685 Highland Avenue, Madison, WI, 53705-2281, USA. ssmccoy@medicine.wisc.edu. 4. Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. 5. Department of Population Sciences, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Abstract
OBJECTIVE: Sjögren's disease (SjD), a highly female predominant systemic autoimmune disease, peaks in perimenopause. Prior studies lack details on timing or type of sex hormone exposure. We examined SjD risk using endogenous and exogenous hormone exposure and related comorbidities. METHODS: We performed a retrospective case-control study of adult women, nested within a population cohort. Cases had SjD diagnosed by a rheumatology provider or two SjD diagnoses from a non-rheumatology provider with a positive anti-SSA antibody or salivary gland biopsy. Cases were age-matched to three SjD-free controls. We calculated modified composite estrogen scores (mCES) and collected demographics, comorbidities, and endogenous and exogenous hormone exposures. Risk ratios were adjusted for demographics. RESULTS: Of 546 SjD cases and 1637 age-matched controls, mCES was not significantly associated with SjD in adjusted models. The top individual hormone exposures associated with SjD included estrogen replacement therapy (ERT; RR 1.78 [95% CI 1.47-2.14]), polycystic ovarian syndrome (1.65 [1.28-2.12]), and hysterectomy without bilateral oophorectomy (1.51 [1.13-2.03]). We identified comorbidities preceding SjD including fibromyalgia, pulmonary disease, diabetes, lymphoma, osteoporosis, peripheral vascular disease, and renal disease. Taking comorbidities into account, we developed a predictive model for SjD that included fibromyalgia (2.50 [1.93-3.25]), osteoporosis (1.84 [1.27-2.66]), hormone replacement therapy (HRT) (1.61 [1.22-2.12]), diabetes (0.27 [0.13-0.50]), and body mass index (BMI) (0.97 [0.95-0.99]). CONCLUSIONS: We report a novel algorithm to improve identifying patients at risk for SjD and describe sex hormone association with SjD. Finally, we report new comorbidities associated with SjD decrease, BMI and diabetes, and increase, lymphoma and osteoporosis.. Key Points •Given female predominance and typical perimenopausal onset, sex hormones should be considered when studying comorbidities in Sjögren's disease. •The top exposures associated with developing Sjögren's disease included fibromyalgia, osteoporosis, and use of hormone replacement therapy. Possible protective factors included prior diabetes and higher body mass index. •We used our newly identified exposures to generate a predictive algorithm, which has potential to improve diagnosis and pathogenic insights into Sjögren's disease.
OBJECTIVE: Sjögren's disease (SjD), a highly female predominant systemic autoimmune disease, peaks in perimenopause. Prior studies lack details on timing or type of sex hormone exposure. We examined SjD risk using endogenous and exogenous hormone exposure and related comorbidities. METHODS: We performed a retrospective case-control study of adult women, nested within a population cohort. Cases had SjD diagnosed by a rheumatology provider or two SjD diagnoses from a non-rheumatology provider with a positive anti-SSA antibody or salivary gland biopsy. Cases were age-matched to three SjD-free controls. We calculated modified composite estrogen scores (mCES) and collected demographics, comorbidities, and endogenous and exogenous hormone exposures. Risk ratios were adjusted for demographics. RESULTS: Of 546 SjD cases and 1637 age-matched controls, mCES was not significantly associated with SjD in adjusted models. The top individual hormone exposures associated with SjD included estrogen replacement therapy (ERT; RR 1.78 [95% CI 1.47-2.14]), polycystic ovarian syndrome (1.65 [1.28-2.12]), and hysterectomy without bilateral oophorectomy (1.51 [1.13-2.03]). We identified comorbidities preceding SjD including fibromyalgia, pulmonary disease, diabetes, lymphoma, osteoporosis, peripheral vascular disease, and renal disease. Taking comorbidities into account, we developed a predictive model for SjD that included fibromyalgia (2.50 [1.93-3.25]), osteoporosis (1.84 [1.27-2.66]), hormone replacement therapy (HRT) (1.61 [1.22-2.12]), diabetes (0.27 [0.13-0.50]), and body mass index (BMI) (0.97 [0.95-0.99]). CONCLUSIONS: We report a novel algorithm to improve identifying patients at risk for SjD and describe sex hormone association with SjD. Finally, we report new comorbidities associated with SjD decrease, BMI and diabetes, and increase, lymphoma and osteoporosis.. Key Points •Given female predominance and typical perimenopausal onset, sex hormones should be considered when studying comorbidities in Sjögren's disease. •The top exposures associated with developing Sjögren's disease included fibromyalgia, osteoporosis, and use of hormone replacement therapy. Possible protective factors included prior diabetes and higher body mass index. •We used our newly identified exposures to generate a predictive algorithm, which has potential to improve diagnosis and pathogenic insights into Sjögren's disease.
Authors: Katherine M Newton; Peggy L Peissig; Abel Ngo Kho; Suzette J Bielinski; Richard L Berg; Vidhu Choudhary; Melissa Basford; Christopher G Chute; Iftikhar J Kullo; Rongling Li; Jennifer A Pacheco; Luke V Rasmussen; Leslie Spangler; Joshua C Denny Journal: J Am Med Inform Assoc Date: 2013-03-26 Impact factor: 4.497
Authors: Hee Kyung Park; Sindana Ilango; Christina M Charriez; Harvey Checkoway; David Riley; David G Standaert; Yvette Bordelon; David R Shprecher; Stephen G Reich; Deborah Hall; Benzi Kluger; Connie Marras; Joseph Jankovic; Richard Dubinsky; Irene Litvan Journal: Mov Disord Date: 2018-02-20 Impact factor: 10.338
Authors: Amy L Kieke; Burney A Kieke; Sarah L Kopitzke; David L McClure; Edward A Belongia; Jeffrey J VanWormer; Robert T Greenlee Journal: Clin Med Res Date: 2014-12-08
Authors: N M Gatto; D Deapen; S Stoyanoff; R Pinder; S Narayan; Y Bordelon; B Ritz Journal: Parkinsonism Relat Disord Date: 2014-08-19 Impact factor: 4.891
Authors: John B Harley; R Hal Scofield; Ke Liu; Biji T Kurien; Sarah L Zimmerman; Kenneth M Kaufman; Diana H Taft; Leah C Kottyan; Sara Lazaro; Carrie A Weaver; John A Ice; Adam J Adler; James Chodosh; Lida Radfar; Astrid Rasmussen; Donald U Stone; David M Lewis; Shibo Li; Kristi A Koelsch; Ann Igoe; Mitali Talsania; Jay Kumar; Jacen S Maier-Moore; Valerie M Harris; Rajaram Gopalakrishnan; Roland Jonsson; James A Lessard; Xianglan Lu; Jacques-Eric Gottenberg; Juan-Manuel Anaya; Deborah S Cunninghame-Graham; Andrew J W Huang; Michael T Brennan; Pamela Hughes; Gabor G Illei; Corinne Miceli-Richard; Edward C Keystone; Vivian P Bykerk; Gideon Hirschfield; Gang Xie; Wan-Fai Ng; Gunnel Nordmark; Per Eriksson; Roald Omdal; Nelson L Rhodus; Maureen Rischmueller; Michael Rohrer; Barbara M Segal; Timothy J Vyse; Marie Wahren-Herlenius; Torsten Witte; Bernardo Pons-Estel; Marta E Alarcon-Riquelme; Joel M Guthridge; Judith A James; Christopher J Lessard; Jennifer A Kelly; Susan D Thompson; Patrick M Gaffney; Courtney G Montgomery; Jeffrey C Edberg; Robert P Kimberly; Graciela S Alarcón; Carl L Langefeld; Gary S Gilkeson; Diane L Kamen; Betty P Tsao; W Joseph McCune; Jane E Salmon; Joan T Merrill; Michael H Weisman; Daniel J Wallace; Tammy O Utset; Erwin P Bottinger; Christopher I Amos; Katherine A Siminovitch; Xavier Mariette; Kathy L Sivils Journal: Arthritis Rheumatol Date: 2016-05 Impact factor: 10.995